10x Genomics Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Goldman Sachs Upgrades NIO (NIO) to Buy
- IBM misses Q2 targets as mainframe and software sales disappoint
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
10x Genomics (TXG) Misses Q1 EPS by 7c
May 4, 2022 4:47 PM EDT10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.38), $0.07 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $114.5 million versus the consensus estimate of $113.34 million.
GUIDANCE:
10x Genomics sees FY2022 revenue of $600-630 million, versus the... More
